Artificial Intelligence | Machine Learning | Natural Language Processing Differentiated Therapeutics | Execution Driven Drug Discovery


Enterprise, Drug Diversion, Drug Discovery, Biological Discovery, Multiobjective Design Boston, Massachusetts, United States

Differentiated Therapeutics

Artificial Intelligence | Machine Learning | Natural Language Processing


Differentiated Therapeutics | Execution Driven Drug Discovery

Differentiated Therapeutics

Drug Diversion, Drug Discovery, Biological Discovery, Multiobjective Design


Boston, Massachusetts, United States

Differentiated Therapeutics (dx/tx) has built the first end-to-end discovery engine for Targeted Protein Degradation (TPD) which drives the discovery and optimization of novel protein degraders designed to eliminate the genetically defined drivers of disease. Due to the highly heterogeneous nature of pharmaceutical development, our field has yet to experience an organization built from the ground up with an end-to-end platform that deploys a custom toolkit of applications for specific problems in the drug development process. Dx/tx fills this gap. We believe our organization can only be successful by discovering differentiated therapeutic development strategies for which our platform drives significant value.

The vast complexity of biological signaling requires protein-protein interactions to impart post-translational modifications and molecules that induce proximity gave us paradigm-shifting medicines like rapamycin, lenalidomide, and pomalidomide. Yet, 95% of nature’s E3-substrate chemical space remains unmapped for its enormous potential - until now. At Differentiated Therapeutics, we’re combining breakthroughs in biophysics, chemoproteomics, molecular simulation, artificial intelligence (AI), and automation to map the conformational basis of induced proximity and to use that map to design novel degrader therapeutics.

 

B2B

1 to 25

Seed

$5M

Scaling Up

2021

 
 

Biotechnology

Leveraging Molecular Dynamics
Success in Clinical Development
Optimization of Protein Degraders

Increase Efficiency

 
 

Analytics
Service

Yes

Active

 
 

   Machine Learning
   Natural Language Processing


Drug Discovery

Drug Discovery


Image

Image

Video

Video

Text

Text

Structured

Structured

 

   Software


Kubernetes

Kubernetes

Python

Python

C/C++

C/C++

Tensorflow

Tensorflow

GitHub

GitHub

AWS Redshift

AWS Redshift

Docker

Docker

AWS Cloud

AWS Cloud


Machine Learning Algorithm

Machine Learning Algorithm

Deep Learning Algorithm

Deep Learning Algorithm

 
 

View All

Senior Research Associate

Director of Biology

 

AI/ML Professionals

Want to work at Differentiated Therapeutics?

We can introduce you to the right person at Differentiated Therapeutics

Talk to our Talent Team

 

1

1

$5M

Company was founded 2021 and it took almost 1 year (Aug 2022) to raise first external round

 
 

Date

Round

$ Raised

Investors

08/01/2022

Seed

$5M

Curie.Bio

Date : 08/01/2022

Round: Seed

$ Raised: $5M

Investors: Curie.Bio

 

Investors

Interested in researching Differentiated Therapeutics?

We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Differentiated Therapeutics

Request a Demo - Deal Souring Platform

 
Bryce Allen

Bryce Allen
Co-founder & CEO

Diala Ezzeddine

Diala Ezzeddine
Co-Founder & COO

 
 

Potential Customers

Interested in what they do or partnership?

Learn more about how they work

Schedule a Call w/ Differentiated Therapeutics